Lung Cancer Trials Ask AI to find trials
RecruitingPhase 1NCT07458347
Official study title

A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

Study summary

The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors with certain KRAS mutations.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedKST-6051 and Gemcitabine/nab-paclitaxel

Plus 6 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · KRAS · Metastatic or stage IV

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 15, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1

Interventional

Where is it offered?9 U.S. locations

Locations may change over time.

Who runs it?Kestrel Therapeutics, Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Kestrel Therapeutics, Inc.
Interventions being studied
Drug: KST-6051; Drug: Gemcitabine/nab-paclitaxel; Drug: Cetuximab; Drug: Pembrolizumab; Drug: mFOLFOX6; Drug: FOLFIRI; Drug: Pemetrexed; Drug: Carboplatin
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
Disease setting
Metastatic or stage IV→
Biomarkers
KRAS→
Treatment approach
Immunotherapy→Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

1. Age ≥ 18 years. 2. Willing and able to give written informed consent. 3. Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor. 4. Documentation of KRAS mutation prior to the first dose of trial drug(s). 5. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. 6. Adequate cardiovascular, hematological, liver, and renal function. 7. Measurable disease at baseline per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1).

Reasons someone may not be able to joinExclusion criteria

1. Central nervous system (CNS) tumors or untreated or unstable metastases. 2. Inability to swallow oral medications. 3. Pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the trial. Other inclusion/

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Cedars-Sinai Medical CenterLos Angeles, California
  • Florida Cancer SpecialistsSarasota, Florida
  • Moffitt Cancer CenterTampa, Florida
  • Mass General Brigham Cancer Institute at Massachusetts General HospitalBoston, Massachusetts
  • Sidney Kimmel Cancer CenterPhiladelphia, Pennsylvania
  • The University of Texas MD Anderson Cancer CenterHouston, Texas
  • NEXT OncologySan Antonio, Texas
  • Huntsman Cancer Institute, University of UtahSalt Lake City, Utah
  • NEXT VirginiaFairfax, Virginia

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 15, 2026. Always confirm current availability with the study team.

View original record ↗